林斌

个人情况介绍、概览

林斌，男，博士，副教授。2002年毕业于沈阳药科大学，获化学制药学士学位，2005年于同校获药物化学硕士学位，2011年获Baylor College of Medicine计算生物学博士学位。博士毕业后，在University of Maryland at Baltimore进行博士后研究。2014年加入沈阳药科大学，任沈阳药科大学药物化学副教授。主要从事药物设计与合成方面的工作。

主要研究方向

研究方向一：新型有机化学反应机理的理论研究

研究方向二：抗脑胶质瘤药物的设计、合成与生物活性的测试

研究方向三：具有生物活性的有机小分子的合成工艺的设计与优化

近年来发表代表性论文

(1) Yanyu Chen; Zhaobo Wang; Wutong Zhao; Shitao Sun; Lu Yang; Junpeng Zhang; Di Zhang; Maosheng Cheng; Bin Lin; Yongxiang Liu ; Ag(I)/PPh3-Catalyzed Diastereoselective Syntheses of Spiro[indole-3,4'-piperidine] Derivatives via Cycloisomerizations of Tryptamine-ynamides., Chemical Communications, 2022, 58: 3051-3054

(2) Guoduan Liang; Yanjun Ji; Hairui Liu; Yadong Pang; Bojun Zhou; Maosheng Cheng; Yang Liu; Bin Lin; Yongxiang Liu ; Silver Triflate/N-Fluorobenzenesulfonimide-Catalyzed Cycloisomerization of Tryptamine-Ynamide to Spiro[indoline -3, 4’-piperidine] Induced by Cation-π-π Interactions between Substrate and Metal Ligand, Advanced Synthesis & Catalysis, 2020, 362: 192-205

(3) Guoduan Liang; Yadong Pang; Yanjun Ji; Kaitong Zhuang; Linji Li; Fukai Xie; Lu Yang; Maosheng Cheng; Bin Lin; Yongxiang Liu ; Supplementary Cover: Diastereoselective Syntheses of Spiro[indoline-3,4’-pyridin]-2-yl Carbamates via AgOTf/Ph3P-Catalyzed Tandem Cyclizations of Tryptamine-Ynesulfonamides, The Journal of Organic Chemistry, 2020, 85: 3010-3019

(4) Chengjun Liu; Zenghui Sun; Fukai Xie; Guoduan Liang; Lu Yang; Yaqiao Li; Maosheng Cheng; Bin Lin; Yongxiang Liu ; Gold(I)-Catalyzed Pathway-Switchable Tandem Cycloisomerizations to Indolizino[8,7-b]indole and Indolo[2,3-a]quinolizine Derivatives, Chemical Communications, 2019, 55: 14418-14421

(5) Yadong Pang; Guoduan Liang; Fukai Xie; HaibinHu; Chuan Du; Xinhang Zhang; Maosheng Cheng; Bin Lin; Yongxiang Liu ; N-Fluorobenzenesulfonimide as a highly effective Ag(i)-catalyst attenuator for tryptamine-derived ynesulfonamide cycloisomerization, Organic & Biomolecular Chemistry, 2019, 8(17): 2247-2257

(6) Zhong, G.; Wang, Y.; Wang, Q.; Wu, M.; Liu, Y.; Sun, S.; Li, Z.; Hao, J.; Dou, P.; Lin, B. Discovery of Novel ID2 Antagonists from Pharmacophore-Based Virtual Screening as Potential Therapeutics for Glioma. Bioorganic & Medicinal Chemistry, 2021, 49, 116427.

(7) Xing, G.; Yi, C.; Dou, P.; Zhi, Z.; Lin, B.; Cheng, M. Recent Progress in the Development of Β2 Adrenergic Receptor Agonists: A Patent Review (2015-2020). Expert Opinion on Therapeutic Patents 2021, 31 (3), 239–246.

(8) Hou, Z.; Li, C.; Liu, Y.; Zhang, M.; Wang, Y.; Fan, Z.; Guo, C.; Lin, B.; Liu, Y. Design, Synthesis and Biological Evaluation of Carbohydrate-Based Sulphonamide Derivatives as Topical Antiglaucoma Agents through Selective Inhibition of Carbonic Anhydrase II. Journal of Enzyme Inhibition and Medicinal Chemistry 2020, 35 (1), 383–390.

(9) Ge, X.; Woo, A. Y.-H.; Xing, G.; Lu, Y.; Mo, Y.; Zhao, Y.; Lan, Y.; Li, J.; Yan, H.; Pan, L.; Zhang, Y.; Lin, B.; Cheng, M. Synthesis and Biological Evaluation of Β2-Adrenoceptor Agonists Bearing the 2-Amino-2-Phenylethanol Scaffold. European Journal of Medicinal Chemistry 2018, 152, 424–435.

(10) He, Q.-J.; Zhou, L.; Lu, L.-W.; Zhao, F.; Huang, X.-X.; Lin, B.; Song, S.-J. Dihydro-β-Agarofuran Sesquiterpenoid Derivatives with Anti-Inflammatory Activity from the Leaves of Tripterygium Wilfordii. Bioorganic Chemistry 2019, 92, 103288.